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and glatiramer acetate) vs. conventional therapy for treatment of
MS. METHODS: Search of electronic databases has identiﬁed 8
models. We evaluated the following sources of uncertainty: 1)
variation in population characteristics (age, gender, country); 2)
sources of data on effectiveness, costs, and health preferences; 3)
modeling assumptions (choice and duration of treatment, long-
term treatment effectiveness, time of treatment initiation and ter-
mination); and 4) model structure (number of health states, study
horizon, and modeling software). RESULTS: Results for inter-
feron beta-1a varied from cost-saving to $2,558,660 (2005 US$)
per quality adjusted of life year (QALY), CE of interferon beta-
1b varied from $10,629/QALY to dominated (more costly and
less effective), and results for glatiramer acetate varied from
$165,201/QALY to dominated. Time horizon and treatment
duration varied from 2 years to lifetime. Studies with longer
treatment duration reported worse (higher) CE. All studies 
used country-speciﬁc cost data and performed some sensitivity
analyses, but only 4 models were evaluated for uncertainty.
CONCLUSIONS: Two out of 8 models found interferons cost-
effective, while glatiramer acetate was not CE based on societal
standards. The differences in models’ results were attributed to
the lack of evidence on long-term treatment effectiveness 
and variation in modeling approaches. Use of DMAs could be
justiﬁed for selected subpopulations, if prices were reduced, 
or if more information on long-term treatment effect becomes
available.
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OBJECTIVE: Migraine is a chronic, episodic condition that
places a tremendous burden on the health care system, employ-
ers, patients and families. This study compared the cost-
effectiveness of treating a migraine with one dose of eletriptan
40mg or sumatriptan 100mg during a 24-hour period.
METHODS: This study used data from a randomized, placebo-
controlled trial to compare the cost-effectiveness of eletriptan 40
mg and sumatriptan 100mg in treating acute migraine. Three
effectiveness measures were compared (sustained headache
response at 1 and 2 hours, and sustained pain-free response at
2 hours) over a 24-hour period in deﬁning treatment success. The
total cost of treating all evaluable patients was deﬁned as the
total cost of the triptans used by patients up to 24 hours after
the ﬁrst dose. The cost per successfully treated patient (CPSTP)
was calculated for each of the three deﬁnitions of treatment
success using the following formula: [CPSTP = Total triptan cost
of treating evaluable patients/ Number of successfully treated
patients] RESULTS: For the 1-hour sustained headache response,
the CPSTP estimates were $103 (95% CI: $89–122) for eletrip-
tan and $149 (95% CI: $126–177) for sumatriptan. For the 2-
hour sustained headache response, the estimates were $48 (95%
CI: $44–53) and $67 (95% CI: $60–76) for eletriptan and suma-
triptan, respectively. For the 2-hour sustained pain-free response,
the estimates were $90 (95% CI: $79–105) for eletriptan and
$151 (95% CI: $127–181), for sumatriptan. The beneﬁt of
eletriptan 40mg over sumatriptan 100mg is clear for all three
measures of success. CONCLUSIONS: The CPSTP, calculated
for each effectiveness measure, was consistently lower for eletrip-
tan 40mg versus sumatriptan 100mg. These results support 
the use of eletriptan 40mg over sumatriptan 100mg in acute
migraine management, and can be used to assist decision makers
in formulary considerations.
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OBJECTIVES: Examine patterns of published economic “value
messages” for anti-epileptic drugs (AEDs). METHODS: Using
literature review best practices, identiﬁed, reviewed, and
abstracted data from comparative economic analyses published
in English and referenced in PubMed or presented at ISPOR. For
each study, documented comparators, “winners” and “losers”,
explanation of economic advantage (if any) study sponsor (if
any), year published, country of interest, and study design.
RESULTS: We identiﬁed 26 studies containing at least one com-
parative economic “value message” for an AED. A total of 57%
(15) were published as manuscripts; 53% (14 of 26) were spon-
sored by a drug manufacturer (4 manuscripts and 10 conference
abstracts); and 38% (10 of 26) were US-oriented. Of the 14
sponsored studies, Ortho-McNeil (topiramate) sponsored 6
(only 1 published; only 1 US-oriented); UCB (levetiracetam) 4;
Novartis (carbamazepine, oxcarbazepine) 3; and GSK (lamot-
rigine) 1. With only one exception (Ortho-McNeil), sponsored
studies generated positive messages for sponsors’ products. The
26 studies generated 39 comparative messages. There was at
least one “winning” message for 11 of the 13 AEDs studied. Top-
iramate was the most frequent “winner” (35% of all messages
expressed economic superiority of topiramate over compara-
tors). Lamotrigine was the most frequent “loser” (45% of all
economic messages). There was at least one message showing
economic superiority over lamotrigine for 7 of the 13 AEDs. For
generically available AEDs, the explanation for cost savings
stemmed from lower drug price, with no evidence of clinical infe-
riority. For levetiracetam, the explanation for cost-effectiveness
stemmed from reduced seizure frequency, a better side effect
proﬁle, and improved adherence. The rationale for topiramate’s
economic advantages was unclear from conference abstracts.
CONCLUSIONS: Several manufacturers of branded AEDs
(Ortho-McNeil, UCB, Novartis) have produced studies describ-
ing their drug’s economic value, while others have done very little
work in this area. Patterns emerge in methods and comparators.
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OBJECTIVE: To assess the cost-effectiveness of pregabalin, a
new add-on antiepileptic, as an adjunct to standard therapy (ST)
in adult patients with refractory partial epilepsy (RPE).
METHODS: We developed a stochastic model to estimate
expected outcomes and costs over one year for a hypothetical
cohort of 1000 RPE patients assumed to receive pregabalin 
(300mg/d, 600mg/d) plus ST or ST alone. Model outcomes
included numbers of days free of seizures (“seizure-free [SF]
days”) and quality-adjusted life-years (QALYs); the latter were
assumed to depend on seizure frequency and side effects. Costs
included those of antiepileptics only. Number of days with
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seizures was estimated for each month of follow-up for ST
patients using data on inter- and intra-patient variability in
seizure frequency. Seizure-days for pregabalin patients were esti-
mated by applying the seizure-rate reduction observed in clini-
cal trials to the estimated rate for ST. Health-state utilities were
estimated using data from a survey of RPE patients. Costs of
antiepileptic drugs were estimated using published US prices.
Cost-effectiveness was calculated alternatively in terms of incre-
mental cost per SF day gained and incremental cost per QALY
gained. RESULTS: Compared to ST alone, add-on therapy with
pregabalin 300mg/d was estimated to yield an average of 41.4
additional SF days and 0.027 additional QALYs over one year;
corresponding estimates for pregabalin 600mg/d were 48.6 
additional SF days and 0.030 additional QALYs. Incremental
cost (mean, 95% CI) per SF day gained was $30 ($24, $39) 
for pregabalin 300mg/d, and $25 ($21, $29) for pregabalin 
600mg/d. Corresponding estimates of the incremental cost per
QALY gained were $46,055 ($35,212, $66,992) and $40,638
($32,816, $50,616). CONCLUSION: The cost-effectiveness
ratio for pregabalin as an adjunct to ST in RPE patients falls
within accepted published thresholds and compares favorably to
those of other add-on antiepileptics.
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OBJECTIVES: To estimate the socio-economic cost and health-
related quality of life (HRQL) for adults with partial epilepsy in
Sweden during 2003. METHODS: 292 patients were randomly
selected from two tertiary centres (University hospital in Lund
and Umeå) and complete data was obtained from 175 patients.
Patients completed a 3 months prospective seizure diary, one ret-
rospective and one prospective health care resource utilization
questionnaire (3 months each). HRQL data were collected using
EQ-5D and a disease-speciﬁc instrument, QOLIE-31. In addi-
tion, data was collected by physicians/nurses by a one-year ret-
rospective patient chart review. Patients were categorized by
most common seizure (sz) type (simple partial, complex partial,
secondary generalized) and sz frequency (sz free, <1sz per
month, >1sz per month). Direct and indirect costs were esti-
mated using prevalence and bottom-up approach. Direct costs
included inpatient care, outpatient care, pharmaceuticals and
social services. Indirect costs were calculated based on the human
capital theory as loss of production due to temporary sick leave
and early retirement. RESULTS: The mean total annual cost per
patient due to partial epilepsy was approximately 100.000 SEK,
indirect costs accounting for approximately 60%. Disease spe-
ciﬁc costs varied between 50.000–170.000 SEK depending on sz
type and frequency. The mean total annual cost per patient based
on all data collected for the patient population was 250.000
SEK, indirect costs accounting for approximately 50%. The
patient population cost varied between 100.000–420.000 SEK
depending on seizure type and frequency. Patients with complex
partial seizure carried the highest cost and had the lowest HRQL.
Patients with no or occasional seizures reported higher HRQL
than patients with more than one sz per month. CONCLU-
SIONS: Partial epilepsy is a serious and expensive disease. The
socio-economic cost increases and HRQL deteriorates with high
seizure frequency increasing frequency of seizures and with fre-
quent complex partial seizures.
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OBJECTIVES: Multiple Sclerosis (MS) is an unpredictable,
chronic neurological disease with a prevalence in Canada of
0.24%. Prevalence of associated pain ranges from 10%–80%
with an average of about 50%. Pain can be musculoskeletal or
nerve related and affects patients’ quality of life. We estimated
the prevalence and the burden of pain due to MS in Canadian
MS patients from the perspective of society. METHODS: The
study protocol was approved by a central Institutional Research
Board and by participating hospitals. 297 patients were recruited
either through MS clinics or the MS Society. Resource utilization
data over the previous six months were collected by telephone
interviews with the patients for direct (drugs, physicians, hospi-
talizations) and indirect costs (time loss). Indirect costs were
based on time loss using the Canadian average industrial wage.
Costing was calculated with Ontario prices and fee schedules,
applying 2004 Canadian dollars ($CAD). Mean cost per patient
were determined (SD, range etc.). The burden was extrapolated
to the Canadian population using national demographics and
prevalence rates for MS and pain in MS. Spearman’s Rho
assessed the relationship between cost and pain severity.
RESULTS: The average age was 49 (±11) years, with 77%
females. The prevalence of pain due to MS in this study sample
was 71% (211/297). The mean total direct cost per patient for
pain in MS over a 6-month period was $2528 (SD = $5695),
with hospitalization as the highest contributor (mean = $711).
The mean total indirect cost for the same period was $669 (SD
= $875). We observed a positive trend between cost and pain
severity measured by the BS-11 scale (Rho = 0.291, p = 0.0001).
The projected six-month burden for Canada was $65,034,679.
CONCLUSIONS: Pain due to MS in Canada is associated with
substantial costs to patients and society.
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OBJECTIVE: Insomnia affects patients’ quality of life and
workplace productivity, and is a risk factor for costly acute
events and chronic diseases. Existing data on the costs of insom-
nia are sparse and outdated. Accordingly, in this study we esti-
mated current societal and employer costs of chronic primary
insomnia in the U.S. METHODS: Prevalence-based cost-of-
illness estimation techniques and data from secondary sources
were used to assess the economic burden of chronic primary
insomnia (i.e., insomnia that is not due to a medical, psychiatric,
or environmental cause) in the U.S. population. Costs included
insomnia medications, insomnia-attributable health events and
chronic conditions (i.e., depression, alcohol abuse, nicotine
dependency, drug abuse, accidental injuries), and lost productiv-
ity. The cost of each insomnia-attributable health consequence
was estimated by multiplying its total cost by its population
attributable risk, which is a function of the prevalence of chronic
